Interstitial lung diseases
Thematic poster
Interstitial lung diseases diagnosis in the COVID-19 era: new tools for new challenges
Methods :
Imaging, Public health, General respiratory patient care, Epidemiology, Endoscopy and interventional pulmonology, Pulmonary function testing
Phenotypes of post covid interstitial lung disease; clinical, radiological, and pathological correlations.
L. Gori(Florence, Italy)
COI
1
Post-COVID interstitial lung disease in symptomatic patients after hospital discharge
L. Polivka(Üröm, Hungary)
COI
2
COVID-19 in interstitial lung diseases: are fibrotic ILDs associated with worse outcomes?
M. Alves Valente(Santo Tirso, Portugal)
COI
3
Non-Detection of Post Covid Pulmonary Fibrosis (PCPF) through HRCT and PFT but possible through Transbronchial Lung Biopsy
V. Tyagi(Meerut (Uttar Pradesh), India)
COI
4
Post-COVID-19 Interstitial Lung Disease: a new entity, what do we deal with?
A. YUKSEL(Ankara, Turkey)
COI
7
Methylprednisolone in the treatment of post-COVID-19 Interstitial Lung Disease (STERCOV-ILD)
A. YUKSEL(Ankara, Turkey)
COI
8
Evolution of diffusion capacity in interstitial lung disease associated with rheumatoid arthritis
M. Vermant(Elsene, Belgium)
COI
9
Persistent Pneumonitis Post-COVID 19: description and risk factors
S. Cuerpo Cardeñosa(Barcelona, Spain)
COI
10
Evaluation of pulmonary function in post-COVID-19 patients
M. Topalovic(Nis, Republic of Serbia)
COI
11
Bleomycin lung toxicity: a retrospective analysis of an old culprit.
D. Moreira Sousa(Santo Tirso, Portugal)
COI
12
Interstitial lung disease in children associated with biological autoimmunity, analysis of a French monocentric retrospective cohort: towards IPAF in children?
A. Hadchouel-Duvergé(Paris, France)
COI
13
Effects of RXC007, a highly potent and selective ROCK2 inhibitor, in ex-vivo and in vivo models of pulmonary fibrosis.
A. Gambardella(Macclesfield, United Kingdom)
COI
14
Diagnostic Performance of the Chest Interstitial Lung Disease Patient Questionnaire
T. Perluk(Givatim, Israel)
COI
15
A retrospective study exploring GAP index as a predictor of mortality in patients with Combined Pulmonary Fibrosis and Emphysema
H. Alsomali(Newcastle upon Tyne, United Kingdom)
COI
16
Early detection of interstitial lung disease using AI-powered spirometry
M. Topalovic(Kessel-lo, Belgium)
COI
17
Clusters of comorbidities in chronic hypersensitivity pneumonitis
T. Prior(Egå, Denmark)
COI
18
Ultrasound as a potential tool to detect interstitial lung disease in the daily clinical setting of patients with rheumatoid arthritis
M. Gutierrez(Mexico City, Mexico)
COI
19
Cudetaxestat, a differentiated phase 2-ready investigational treatment for idiopathic pulmonary fibrosis
B. Elmankabadi(San Francisco, United States)
COI
20
. . .
